Teijin (3401) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
27 Feb, 2026Vision and business model
Focus on a customer-centric business model to solve customer problems and drive stable profit, with a shift toward growth in high-value sectors like fibers, healthcare, and advanced materials.
Transformation of the business portfolio includes divestment of underperforming businesses and integration with strategic partners.
Battery materials & membrane business positioning
Prioritizes high-growth markets: batteries, semiconductors, and hydrogen, with a fivefold top-line expansion in five years.
From April 2026, will integrate with resin & plastic processing to enhance solutions for automotive electronics, optical components, and office equipment.
Market outlook and growth drivers
Targets markets expected to grow significantly over the next decade, driven by decarbonization, electrification, and digitalization.
Battery, semiconductor, and hydrogen markets forecast to multiply in size by 2035, with hydrogen production expected to grow 73-fold.
Latest events from Teijin
- Revenue and profit fell on impairments and divestitures, but Healthcare grew and dividend is stable.3401
Q3 202623 Feb 2026 - Profit and revenue growth offset healthcare headwinds, with rare disease and home care focus.3401
Q3 202523 Dec 2025 - Growth centers on high-value, sustainable solutions and global market expansion.3401
Investor Day 202519 Dec 2025 - Major impairment and business transfer drive net loss; outlook cut, dividend steady.3401
Q2 20261 Dec 2025 - FY2024 saw profit recovery and portfolio transformation; higher FY2025 income expected.3401
Q4 202520 Nov 2025 - Profits and revenue fell in Q1 FY2025, but full-year outlook and dividend remain steady.3401
Q1 20265 Aug 2025 - Teijin accelerates healthcare growth with a focus on rare diseases, home care, and innovation.3401
Investor Update13 Jun 2025 - Q1 FY2024 revenue and profit surged, with IT business divestiture and IFRS adoption underway.3401
Q1 202513 Jun 2025 - Impairment losses offset strong 1H growth; asset sales and restructuring support FY2024 outlook.3401
Q2 202513 Jun 2025